OncoSignal
Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma

Chronic myeloid leukemia

Asciminib and the STAMP inhibitors, treatment-free remission and resistance after ponatinib.

Live from ClinicalTrials.gov and PubMed, fetched 2026-11-11 15:26 UTC. Every row links to its source record.

Registry changes (new trials, status, phase, endpoint and readout-date changes, results) come from the OncoSignal store, last verified against ClinicalTrials.gov 2026-11-11 08:26 UTC.

Phase advances
1
since 2026-07-14
New Ph2+ trials
3
Results posted
0
Readouts due
6
primary completion reached
Trial papers
2
PubMed, last 60 days
  1. Paper
  2. Readout due
    Readout due: TUSCANY reached primary completion

    Aptose Biosciences Inc.. Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

  3. Phase advance
    ELVN-001 advances to Ph3 (indication level)

    Enliven Therapeutics posted ENABLE-2: A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs

  4. New trial
    New Ph3 trial: ENABLE-2 (NCT07905183)

    Enliven Therapeutics. A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs

  5. New trial
    New Ph3 trial: NCT07885293

    Jiangsu Hansoh Pharmaceutical Co., Ltd.. A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

  6. New trial
    New Ph2 trial: MPN-RC 127 (NCT07872709)

    John Mascarenhas. Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms

  7. Readout due
    Readout due: NCT03817398 reached primary completion

    Children's Oncology Group. Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

  8. Paper
  9. Readout due
    Readout due: NAUT reached primary completion

    European LeukemiaNet. 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients

  10. Readout due
    Readout due: ACCESS reached primary completion

    Center for International Blood and Marrow Transplant Research. HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

  11. Readout due
    Readout due: NCT03672539 reached primary completion

    M.D. Anderson Cancer Center. Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

  12. Readout due
    Readout due: NCT05589896 reached primary completion

    Ossium Health, Inc.. A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

A phase advance is an asset's first trial at a higher phase than any earlier trial of the same asset in this indication. Readout due means the registry's primary completion date has passed; it is not a disclosure.